Nationwide Italian registry reveals who responds best to rituximab in NMOSD and MOGAD
A 664-patient Italian registry study identifies sex and onset phenotype as predictors of rituximab response in AQP4-positive NMOSD and MOGAD.
A 664-patient Italian registry study identifies sex and onset phenotype as predictors of rituximab response in AQP4-positive NMOSD and MOGAD.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine